Precision Medicines for Retinal Lipid Metabolism-Related Pathologies

Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in...

Descripción completa

Detalles Bibliográficos
Autores: Ana, Raquel da, Gliszczyńska, Anna, Sanchez-Lopez, Elena, Garcia, Maria L., Krambeck, Karolline, Kovacevic, Andjelka, Souto, Eliana B.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/308773
Acceso en línea:http://hdl.handle.net/10261/308773
https://api.elsevier.com/content/abstract/scopus_id/85154070717
Access Level:acceso abierto
Palabra clave:Targeting lipid metabolism
Lipid oxidation
Nanoparticles
Ocular lipid metabolism
Peroxisomal oxidation
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
id ES_f4efcffd4c558c4e3c261bb75bf1b005
oai_identifier_str oai:digital.csic.es:10261/308773
network_acronym_str ES
network_name_str España
repository_id_str
spelling Precision Medicines for Retinal Lipid Metabolism-Related PathologiesAna, Raquel daGliszczyńska, AnnaSanchez-Lopez, ElenaGarcia, Maria L.Krambeck, KarollineKovacevic, AndjelkaSouto, Eliana B.Targeting lipid metabolismLipid oxidationNanoparticlesOcular lipid metabolismPeroxisomal oxidationhttp://metadata.un.org/sdg/3Ensure healthy lives and promote well-being for all at all agesOxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch's membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.The research was funded by the Fundação para a Ciência e a Tecnologia (FCT) for the scholarship 2020.04729.BD granted to Raquel da Ana. Eliana B. Souto acknowledges the national funds from FCT—Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences—UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy—i4HB.Peer reviewedMultidisciplinary Digital Publishing InstituteGliszczyńska, Anna [0000-0002-0218-6369]Krambeck, Karolline [0000-0001-9645-4020]Souto, Eliana B. [0000-0002-9737-6017]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202320232023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/308773https://api.elsevier.com/content/abstract/scopus_id/85154070717reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)Ingléshttps://doi.org/10.3390/jpm13040635Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3087732026-05-22T06:33:51Z
dc.title.none.fl_str_mv Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
title Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
spellingShingle Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
Ana, Raquel da
Targeting lipid metabolism
Lipid oxidation
Nanoparticles
Ocular lipid metabolism
Peroxisomal oxidation
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
title_short Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
title_full Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
title_fullStr Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
title_full_unstemmed Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
title_sort Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
dc.creator.none.fl_str_mv Ana, Raquel da
Gliszczyńska, Anna
Sanchez-Lopez, Elena
Garcia, Maria L.
Krambeck, Karolline
Kovacevic, Andjelka
Souto, Eliana B.
author Ana, Raquel da
author_facet Ana, Raquel da
Gliszczyńska, Anna
Sanchez-Lopez, Elena
Garcia, Maria L.
Krambeck, Karolline
Kovacevic, Andjelka
Souto, Eliana B.
author_role author
author2 Gliszczyńska, Anna
Sanchez-Lopez, Elena
Garcia, Maria L.
Krambeck, Karolline
Kovacevic, Andjelka
Souto, Eliana B.
author2_role author
author
author
author
author
author
dc.contributor.none.fl_str_mv Gliszczyńska, Anna [0000-0002-0218-6369]
Krambeck, Karolline [0000-0001-9645-4020]
Souto, Eliana B. [0000-0002-9737-6017]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Targeting lipid metabolism
Lipid oxidation
Nanoparticles
Ocular lipid metabolism
Peroxisomal oxidation
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
topic Targeting lipid metabolism
Lipid oxidation
Nanoparticles
Ocular lipid metabolism
Peroxisomal oxidation
http://metadata.un.org/sdg/3
Ensure healthy lives and promote well-being for all at all ages
description Oxidation of lipids and lipoproteins contributes to inflammation processes that promote the development of eye diseases. This is a consequence of metabolism dysregulation; for instance, that of the dysfunctional peroxisomal lipid metabolism. Dysfunction of lipid peroxidation is a critical factor in oxidative stress that causes ROS-induced cell damage. Targeting the lipid metabolism to treat ocular diseases is an interesting and effective approach that is now being considered. Indeed, among ocular structures, retina is a fundamental tissue that shows high metabolism. Lipids and glucose are fuel substrates for photoreceptor mitochondria; therefore, retina is rich in lipids, especially phospholipids and cholesterol. The imbalance in cholesterol homeostasis and lipid accumulation in the human Bruch's membrane are processes related to ocular diseases, such as AMD. In fact, preclinical tests are being performed in mice models with AMD, making this area a promising field. Nanotechnology, on the other hand, offers the opportunity to develop site-specific drug delivery systems to ocular tissues for the treatment of eye diseases. Specially, biodegradable nanoparticles constitute an interesting approach to treating metabolic eye-related pathologies. Among several drug delivery systems, lipid nanoparticles show attractive properties, e.g., no toxicological risk, easy scale-up and increased bioavailability of the loaded active compounds. This review analyses the mechanisms involved in ocular dyslipidemia, as well as their ocular manifestations. Moreover, active compounds as well as drug delivery systems which aim to target retinal lipid metabolism-related diseases are thoroughly discussed.
publishDate 2023
dc.date.none.fl_str_mv 2023
2023
2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/308773
https://api.elsevier.com/content/abstract/scopus_id/85154070717
url http://hdl.handle.net/10261/308773
https://api.elsevier.com/content/abstract/scopus_id/85154070717
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://doi.org/10.3390/jpm13040635
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
publisher.none.fl_str_mv Multidisciplinary Digital Publishing Institute
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424517679415296
score 15.811543

Similares en LA Referencia